Serotonin 2A receptors differentially contribute to abuse-related effects of cocaine and cocaine-induced nigrostriatal and mesolimbic dopamine overflow in nonhuman primates. 2013

Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30322, USA.

Two of the most commonly used procedures to study the abuse-related effects of drugs in laboratory animals are intravenous drug self-administration and reinstatement of extinguished behavior previously maintained by drug delivery. Intravenous self-administration is widely accepted to model ongoing drug-taking behavior, whereas reinstatement procedures are accepted to model relapse to drug taking following abstinence. Previous studies indicate that 5-HT2A receptor antagonists attenuate the reinstatement of cocaine-maintained behavior but not cocaine self-administration in rodents. Although the abuse-related effects of cocaine have been closely linked to brain dopamine systems, no previous study has determined whether this dissociation is related to differential regulation of dopamine neurotransmission. To elucidate the neuropharmacological and neuroanatomical mechanisms underlying this phenomenon, we evaluated the effects of the selective 5-HT2A receptor antagonist M100907 on intravenous cocaine self-administration and drug- and cue-primed reinstatement in rhesus macaques (Macaca mulatta). In separate subjects, we evaluated the role of 5-HT2A receptors in cocaine-induced dopamine overflow in the nucleus accumbens (n = 4) and the caudate nucleus (n = 5) using in vivo microdialysis. Consistent with previous studies, M100907 (0.3 mg/kg, i.m.) significantly attenuated drug- and cue-induced reinstatement but had no significant effects on cocaine self-administration across a range of maintenance doses. Importantly, M100907 (0.3 mg/kg, i.m.) attenuated cocaine-induced (1.0 mg/kg, i.v.) dopamine overflow in the caudate nucleus but not in the nucleus accumbens. These data suggest that important abuse-related effects of cocaine are mediated by distinct striatal dopamine projection pathways.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D010880 Piperidines A family of hexahydropyridines.
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females
D005464 Fluorobenzenes Derivatives of BENZENE that contain FLUORINE. Fluorobenzene
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin
D017551 Microdialysis A technique for measuring extracellular concentrations of substances in tissues, usually in vivo, by means of a small probe equipped with a semipermeable membrane. Substances may also be introduced into the extracellular space through the membrane.
D044402 Receptor, Serotonin, 5-HT2A A serotonin receptor subtype found widely distributed in peripheral tissues where it mediates the contractile responses of variety of tissues that contain SMOOTH MUSCLE. Selective 5-HT2A receptor antagonists include KETANSERIN. The 5-HT2A subtype is also located in BASAL GANGLIA and CEREBRAL CORTEX of the BRAIN where it mediates the effects of HALLUCINOGENS such as LSD. Serotonin 2A Receptor,5-HT(2A) Receptor,5-HT2A Receptor,Receptor, Serotonin 2A,Serotonin 2A Receptors,5 HT2A Receptor,Receptor, 5-HT2A,Receptors, Serotonin 2A

Related Publications

Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
October 2013, Journal of sleep research,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
November 1993, Brain research,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
April 2008, The Chinese journal of physiology,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
January 1997, Brain research bulletin,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
May 1979, Pharmacology, biochemistry, and behavior,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
January 1987, Psychopharmacology,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
January 2012, Experimental diabetes research,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
June 1990, The American journal of psychiatry,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
September 2017, Psychopharmacology,
Kevin S Murnane, and Jake Winschel, and Karl T Schmidt, and LaShaya M Stewart, and Samuel J Rose, and Kejun Cheng, and Kenner C Rice, and Leonard L Howell
January 2020, Addiction biology,
Copied contents to your clipboard!